Encephalitis, Myelitis, and Encephalomyelitis – Cannabis THC : CBD Ratios

Encephalitis, Myelitis, and Encephalomyelitis Research Dashboard

9

Primary Studies

4

Related Studies

13

Total Studies

Clinical Studies

0

Double-blind human trials

0

Clinical human trials

Pre-Clinical Studies

0

Meta-analyses/Reviews

9

Animal studies

0

Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 13 studies associated with Encephalitis, Myelitis, and Encephalomyelitis.

Here is a small sampling of Encephalitis, Myelitis, and Encephalomyelitis studies by title:


Components of the Encephalitis, Myelitis, and Encephalomyelitis Research Dashboard

  • Dosing information available for Encephalitis, Myelitis, and Encephalomyelitis
  • Chemotype guidance for treating Encephalitis, Myelitis, and Encephalomyelitis with cannabis
  • Synopsis of cannabis research for Encephalitis, Myelitis, and Encephalomyelitis
  • Individual study details for Encephalitis, Myelitis, and Encephalomyelitis

Ready to become a subscriber? Go to our PRICING page.

Select New Condition

Search By Keyword

Filter Condition

Members can filter by the following criteria:

  • Study Type
  • Chemotype
  • Cannabinoids & Endocannabinoids
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Encephalitis, Myelitis, and Encephalomyelitis

Description of Encephalitis, Myelitis, and Encephalomyelitis

Encephalitis is an inflammation of the brain. It is most commonly caused by a virus such as, herpes, West Nile, or equine encephalitis or by live virus vaccination e.g. MMR-II, although it may also be produced by bacteria (e.g., syphilis, bacterial meningitis, Lyme disease), parasites (e.g., malaria), or an over-reactive immune response to an inflammation or secondary infection (e.g., measles, mumps, or rubella). Depending on underlying cause orthodox treatment modalities usually include pharmaceutical intervention such as anti-inflammatory drugs, immunosuppressants (steroids), or antivirals for example. Encephalomyelitis is an autoimmune disorder (the immune system attacks the body itself) characterized by inflammation of the brain and the spinal cord. This condition expresses itself in a handful of forms such as acute disseminated (post infectious) encephalomyelitis, a type resembling multiple sclerosis and characterized by the destruction of myelin sheaths (the insulating tissue of nerve fibers) or myelin oligodendrocyte glycoprotein antibody disorders (MOGAD) associated encephalomyelitis. While exact causes are to be determined contributing factors may include in addition to an auto-immune response, microbial infections or exposure to certain vaccines (e.g. Measles, Mumps, and Rubella Virus Vaccine Live) for instance. Orthodox treatments are pharmaceutical in nature (e.g. steroids) and are geared to reduce overly reactive inflammatory responses.

Disease Classification

Condition: Encephalitis and Myelitis
Disease Family: Inflammatory Disease, Infectious Disease
Organ System: Nervous System
ICD-10 Chapter: Diseases of the Nervous System
ICD-10 Code: G04

Encephalitis, Myelitis, and Encephalomyelitis Symptoms:

Numbness, tingling, weakness, paralysis, ataxia, pain, poor sphincter control (e.g. bladder, bowel), nausea and vomiting, seizure, coma

Also known as:

Encephalomyelitis, Myelitis, Acute ascending myelitis, EAE

Drug Interactions

THC Interaction with Pharmaceutical Drugs

  • THC can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol, for example. 
  • THC is metabolized by and an inhibitor of a number of enzymatic liver pathways referred to as cytochrome P450. There are more than 50 enzymes belonging to this enzyme family, a number of which are responsible for the breakdown of common drugs such as antidepressants (e.g. amitriptyline, doxepine, fluvoxamine), antipsychotics (haloperidol, clozapine, stelazine), or beta-blockers (propranolol, theophylline, warfarin).  Thus patients taking these classes of medication may find that THC increases the concentration and effects of these drugs as well as the duration of their effects.
  • Clinical observation suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.

CBD Interaction with Pharmaceutical Drugs

  • CBD may alter action on metabolic enzymes (certain drug-transport mechanisms), and as such may alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects. 
  • Groups of drugs affected include: anti-epileptic drugs, psychiatric drugs, and drugs affecting metabolic enzymes, for example.
  • Clinical observations suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD

Dosing Considerations

THC Dosage Considerations

  • THC micro dose:  0.1 mg to 0.4 mg (0.001mg/kg to 0.005mg/kg)
  • THC low dose:  0.5 mg to 5 mg (0.006mg/kg to 0.06mg/kg)
  • THC medium dose:  6 mg to 20 mg (0.08mg/kg to 0.27mg/kg)
  • THC high dose:  21 mg to 50+ mg (0.28mg/kg to 0.67mg/kg)
Formula for converting a set dose into mg/kg considerations: mg ÷ kg = mg/kg
(sample conversion calculated on a person weighing 75kg)

CBD Dosage Considerations

  • CBD low dose:  0.4 mg to 19 mg (0.005mg/kg to 0.25mg/kg)
  • CBD medium dose: 20 mg to 99 mg (0.26mg/kg to 1.32mg/kg)
  • CBD high dose:  100 mg to 800+ mg (1.33mg/kg to 10.7mg/kg)
  • (upper limits tested ~1,500mg)
Formula for converting a set dose into mg/kg considerations: mg ÷ kg = mg/kg
(sample conversion calculated on a person weighing 75kg)
Top

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.